188 related articles for article (PubMed ID: 36083713)
1. Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up.
Parisi M; Dogliotti I; Clerico M; Bertuzzo D; Benevolo G; Orsucci L; Schiavetti I; Cavallo R; Cavallo F; Ragaini S; Di Liberto A; Ferrante M; Bondielli G; Artusi CA; Drandi D; Lopiano L; Ferrero B; Ferrero S
Eur J Neurol; 2022 Dec; 29(12):3611-3622. PubMed ID: 36083713
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
3. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.
Kawagashira Y; Koike H; Ohyama K; Hashimoto R; Iijima M; Adachi H; Katsuno M; Chapman M; Lunn M; Sobue G
J Neurol Sci; 2015 Jan; 348(1-2):67-73. PubMed ID: 25467141
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD002827. PubMed ID: 27701752
[TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
8. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in chronic immune mediated neuropathies: a systematic review.
Chaganti S; Hannaford A; Vucic S
Neuromuscul Disord; 2022 Aug; 32(8):621-627. PubMed ID: 35672205
[TBL] [Abstract][Full Text] [Related]
10. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Castellani F; Visentin A; Schirinzi E; Salvalaggio A; Cacciavillani M; Candiotto C; Baratè C; Cellini A; Bertorelle R; Siciliano G; Trentin L; Briani C
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37137530
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
12. [Anti-MAG paraproteinemic demyelinating polyneuropathy: a clinical, biological, electrophysiological and anatomopathological descriptive study of a 13-patients' cohort].
Launay M; Delmont E; Benaim C; Sacconi S; Butori C; Desnuelle C
Rev Neurol (Paris); 2009 Dec; 165(12):1071-9. PubMed ID: 19487003
[TBL] [Abstract][Full Text] [Related]
13. Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies.
Galassi G; Tondelli M; Ariatti A; Benuzzi F; Nichelli P; Valzania F
Int J Neurosci; 2017 May; 127(5):439-447. PubMed ID: 27188752
[TBL] [Abstract][Full Text] [Related]
14. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
15. [Anti-myelin-associated glycoprotein antibody positive IgM monoclonal gammopathy related peripheral neuropathy: 11 cases and literature review].
Gao XM; Jia MN; Qian M; Ren HT; Zhang L; Shen KN; Cao XX; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):901-905. PubMed ID: 31856437
[No Abstract] [Full Text] [Related]
16. Clinical-neurophysiological correlations in a series of patients with IgM-related neuropathy.
Luigetti M; Padua L; Mazza S; Rossini PM; Sabatelli M; Lo Monaco M
Clin Neurophysiol; 2013 Sep; 124(9):1899-903. PubMed ID: 23643315
[TBL] [Abstract][Full Text] [Related]
17. [A case of IgM paraproteinemic neuropathy associated with anti-sulfated glucuronic paragloboside (SGPG) IgG antibody without anti-myelin-associated glycoprotein (MAG) activity].
Nakamura H; Endo M; Sugawara E; Kuwahara M; Kusunoki S; Tanaka F; Takahashi T
Rinsho Shinkeigaku; 2013; 53(10):799-802. PubMed ID: 24225562
[TBL] [Abstract][Full Text] [Related]
18. Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings.
Vrethem M; Reiser N; Lauermann C; Svanborg E
Acta Neurol Scand; 2010 Jul; 122(1):52-7. PubMed ID: 20003083
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy.
Gazzola S; Delmont E; Franques J; Boucraut J; Salort-Campana E; Verschueren A; Sagui E; Hubert AM; Pouget J; Attarian S
J Neurol Sci; 2017 Jun; 377():144-148. PubMed ID: 28477685
[TBL] [Abstract][Full Text] [Related]
20. Widening of myelin lamellae in polyneuropathy with immunoglobulin-M monoclonal gammopathy, without activity against myelin-associated glycoprotein, responsive to treatment.
Vallat JM; Deschamps N; Richard L; Magy L; Devaux J; Mathis S
Neuromuscul Disord; 2022 Aug; 32(8):678-681. PubMed ID: 35618575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
